BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Petersen J, Buti M. Considerations for the long-term treatment of chronic hepatitis B with nucleos(t)ide analogs. Expert Rev Gastroenterol Hepatol. 2012;6:683-693; quiz 694. [PMID: 23237254 DOI: 10.1586/egh.12.52] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Chokshi S, Cooksley H, Riva A, Phillips S, Williams R, Gaggar A, Naoumov NV. Identification of serum cytokine profiles associated with HBeAg seroconversion following antiviral treatment interruption. Viral Immunol. 2014;27:235-244. [PMID: 24797262 DOI: 10.1089/vim.2014.0022] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
2 Kountouras DA. Viral Hepatitis B and C. Cure or Treatment? Thalassemia Reports 2014;4:4870. [DOI: 10.4081/thal.2014.4870] [Reference Citation Analysis]
3 Villain P, Gonzalez P, Almonte M, Franceschi S, Dillner J, Anttila A, Park JY, De Vuyst H, Herrero R. European Code against Cancer 4th Edition: Infections and Cancer. Cancer Epidemiology 2015;39:S120-38. [DOI: 10.1016/j.canep.2015.10.006] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
4 Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 2015; 148: 221-244. e3. [PMID: 25447852 DOI: 10.1053/j.gastro.2014.10.038] [Cited by in Crossref: 274] [Cited by in F6Publishing: 249] [Article Influence: 34.3] [Reference Citation Analysis]
5 Bernieh B. Viral hepatitis in hemodialysis: An update. J Transl Int Med. 2015;3:93-105. [PMID: 27847896 DOI: 10.1515/jtim-2015-0018] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 3.7] [Reference Citation Analysis]
6 Hadziyannis SJ, Vassilopoulos D, Sevastianos V, Hadziyannis E. Can Nucleos(t)ide Analogue (NA) Therapy Ever be Stopped in HBeAg-Negative Chronic Hepatitis B? Curr Hepatology Rep 2014;13:256-63. [DOI: 10.1007/s11901-014-0236-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
7 Fernández-Rodríguez CM, Gutiérrez-García ML. Prevention of hepatocellular carcinoma in patients with chronic hepatitis B. World J Gastrointest Pharmacol Ther 2014; 5(3): 175-182 [PMID: 25133046 DOI: 10.4292/wjgpt.v5.i3.175] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
8 Ke W, Liu L, Zhang C, Ye X, Gao Y, Zhou S, Yang Y. Comparison of efficacy and safety of tenofovir and entecavir in chronic hepatitis B virus infection: a systematic review and meta-analysis. PLoS One. 2014;9:e98865. [PMID: 24905092 DOI: 10.1371/journal.pone.0098865] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 5.4] [Reference Citation Analysis]
9 Kayaaslan B, Guner R. Adverse effects of oral antiviral therapy in chronic hepatitis B. World J Hepatol 2017; 9(5): 227-241 [PMID: 28261380 DOI: 10.4254/wjh.v9.i5.227] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
10 Lomonosova E, Tavis JE. In Vitro Enzymatic and Cell Culture-Based Assays for Measuring Activity of HBV RNaseH Inhibitors. Methods Mol Biol 2017;1540:179-92. [PMID: 27975316 DOI: 10.1007/978-1-4939-6700-1_14] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
11 Kao JH, Asselah T, Dou XG, Hamed K. Telbivudine therapy for chronic hepatitis B: A journey to identify super-responders and to optimize treatment using the roadmap model. J Gastroenterol Hepatol 2017;32:73-81. [PMID: 27515408 DOI: 10.1111/jgh.13512] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
12 Shouval D. Focus. Journal of Hepatology 2013;58:641-2. [DOI: 10.1016/j.jhep.2013.01.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
13 Kong LN, Zhu WF, He S, Wang T, Guo Y. Development and preliminary validation of the chronic hepatitis B self-management scale. Appl Nurs Res 2018;41:46-51. [PMID: 29853213 DOI: 10.1016/j.apnr.2018.03.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
14 Kong LN, Guo Y, Qin B, Peng X, Zhu WF. Development of Self-Management Indicators for Chronic Hepatitis B Patients on Antiviral Therapy: Results of a Chinese Delphi Panel Survey. PLoS One 2015;10:e0134125. [PMID: 26327606 DOI: 10.1371/journal.pone.0134125] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
15 Kim MN, Hwang SG, Rim KS, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Kim SU. Validation of PAGE-B model in Asian chronic hepatitis B patients receiving entecavir or tenofovir. Liver Int 2017;37:1788-95. [PMID: 28418595 DOI: 10.1111/liv.13450] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 5.4] [Reference Citation Analysis]
16 Gerlich WH. Medical virology of hepatitis B: how it began and where we are now. Virol J. 2013;10:239. [PMID: 23870415 DOI: 10.1186/1743-422x-10-239] [Cited by in Crossref: 152] [Cited by in F6Publishing: 74] [Article Influence: 16.9] [Reference Citation Analysis]
17 Kim WR, Loomba R, Berg T, Aguilar Schall RE, Yee LJ, Dinh PV, Flaherty JF, Martins EB, Therneau TM, Jacobson I, Fung S, Gurel S, Buti M, Marcellin P. Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B. Cancer 2015;121:3631-8. [PMID: 26177866 DOI: 10.1002/cncr.29537] [Cited by in Crossref: 109] [Cited by in F6Publishing: 97] [Article Influence: 15.6] [Reference Citation Analysis]
18 Roade L, Riveiro-Barciela M, Esteban R, Buti M. Long-term efficacy and safety of nucleos(t)ides analogues in patients with chronic hepatitis B. Ther Adv Infect Dis 2021;8:2049936120985954. [PMID: 33614029 DOI: 10.1177/2049936120985954] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]